Clinical observation of Dachaihu decoction in the treatment of Irascibility hyperactivity syndrome(overabundant liver-fire syndrom) of hypertensio

Not Applicable

• Conditions: Essential hypertension

• Registration Number: ITMCTR2000003134
• Lead Sponsor: Affiliated Hospital of Shandong University of TCM

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Meet the diagnostic criteria of western medicine for essential hypertension and the diagnostic criteria for the syndrome of dizziness, irascibility and hyperactivity; Hypertension is grade 1, and the risk level is low;
2. Blood pressure was stable in the past 4 weeks, without the treatment of traditional Chinese medicine or proprietary Chinese medicine, without the treatment of western medicine or western medicine;
3. Between 18 and 75 years old, gender is not limited;
4. Patients who volunteer to participate in the trial and sign the informed consent and cooperate with various investigations and tests;
5. Women of child-bearing age should have a negative pregnancy test and agree to take non-drug contraceptive measures during the test period.

Exclusion Criteria

1. With secondary hypertension, refractory hypertension, malignant hypertension, acute and subacute hypertension, white coat hypertension and unstable blood pressure;
2. Pregnant and lactating women, women of child-bearing age do not agree to use contraceptive measures during the experiment;
3. Have mental illness, can't cooperate very well;
4. The patients with serious heart disease, severe neurosis and heart, liver and kidney dysfunction confirmed by examination;
5. Severe endocrine, hematopoietic system, liver, kidney and other primary diseases, malignant tumors, mental patients.
6. With uncorrected hyperthyroidism, hypothyroidism;
7. Patients with nephrotic syndrome, diabetes mellitus and acute hepatobiliary disease;
8. People who have suffered from serious cerebrovascular accidents, heart diseases, severe trauma, major surgery and other primary diseases with unstable general conditions and poor prognosis within 6 months.
9. Cases of Data collected with other disease; Patients who are in the course of drug treatment and affect the investigational drug observer;
9. Those who have participated in clinical trials of other drugs within three months;
10. Other conditions that the researchers considered inappropriate for inclusion were eliminated.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified